GATA1-binding site within the +58 erythroid-specific enhancer of the BCL11A gene (BCL11A +58 enhancer)

The GATA1-binding site within the +58 erythroid-specific enhancer of the BCL11A gene is a critical genomic regulatory element located approximately 58 kilobases downstream of the BCL11A transcription start site (Bauer et al., 2013). This enhancer is essential for the expression of BCL11A, a zinc-finger transcription factor that acts as a potent repressor of fetal hemoglobin (HbF) in adult erythroid cells (Canver et al., 2015). By binding to this specific site, the transcription factor GATA1 promotes BCL11A expression, which in turn silences the gamma-globin genes. Therapeutic disruption of this binding site using CRISPR-Cas9 technology, as seen in exagamglogene autotemcel, prevents BCL11A production specifically in the erythroid lineage (Frangoul et al., 2021). This reduction in BCL11A allows for the reactivation of gamma-globin and the production of HbF, which can compensate for defective or absent adult hemoglobin in patients with sickle cell disease or beta-thalassemia (FDA, 2023). This targeted approach avoids systemic downregulation of BCL11A, which is necessary for normal B-cell development and other non-erythroid functions.

Other names

BCL11A erythroid-specific enhancer+58 kb enhancer of BCL11AGATA1 motif in BCL11A enhancerBCL11A +58 enhancer

CRISPR-Cas9-mediated gene editing to disrupt the GATA1 binding motif, leading to reduced BCL11A expression specifically in erythroid cells and subsequent induction of fetal hemoglobin (HbF).